CN107428825A - 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 - Google Patents
治疗及/或预防肿瘤生长、侵袭及/或转移的方法 Download PDFInfo
- Publication number
- CN107428825A CN107428825A CN201580055045.1A CN201580055045A CN107428825A CN 107428825 A CN107428825 A CN 107428825A CN 201580055045 A CN201580055045 A CN 201580055045A CN 107428825 A CN107428825 A CN 107428825A
- Authority
- CN
- China
- Prior art keywords
- cancer
- expression
- cell
- tumour
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Abstract
Description
Claims (17)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462062202P | 2014-10-10 | 2014-10-10 | |
US62/062,202 | 2014-10-10 | ||
PCT/US2015/054960 WO2016057933A1 (en) | 2014-10-10 | 2015-10-09 | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107428825A true CN107428825A (zh) | 2017-12-01 |
Family
ID=55653862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580055045.1A Pending CN107428825A (zh) | 2014-10-10 | 2015-10-09 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20180265874A1 (zh) |
CN (1) | CN107428825A (zh) |
TW (1) | TWI669123B (zh) |
WO (1) | WO2016057933A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022042537A1 (zh) * | 2020-08-24 | 2022-03-03 | 江苏恒瑞医药股份有限公司 | TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途 |
WO2022174451A1 (zh) * | 2021-02-22 | 2022-08-25 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
BR112019006074A2 (pt) | 2016-09-29 | 2019-06-18 | Beijing Hanmi Pharmaceutical Co Ltd | heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo |
AU2017339561B2 (en) | 2016-10-07 | 2024-02-01 | Secarna Pharmaceuticals Gmbh & Co. Kg | Novel approach for treating cancer |
EP3533804A4 (en) | 2016-11-18 | 2020-06-17 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF |
CN107058315B (zh) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
TWI788321B (zh) | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
US11440963B2 (en) | 2017-05-09 | 2022-09-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies |
WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
EP3750920A4 (en) | 2018-02-11 | 2021-11-10 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY IN HETERODIMER FORM SIMILAR TO A NATURAL ANTI-PD-1 / ANTI-VEGF ANTIBODY STRUCTURE AND PRODUCTION OF IT |
WO2020118208A1 (en) * | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
AU2020269886A1 (en) | 2019-05-03 | 2021-12-02 | Secarna Pharmaceuticals Gmbh & Co. Kg | PD-L1 antisense oligonucleotides for use in tumor treatment |
AU2020352441A1 (en) * | 2019-09-12 | 2022-04-28 | Sirnaomics, Inc. | Co-delivery of TGF-β siRNA and PDL1 siRNA to treat cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070155685A1 (en) * | 2004-02-27 | 2007-07-05 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
CN102428179A (zh) * | 2009-03-06 | 2012-04-25 | 国立大学法人三重大学 | 用于增强t细胞功能的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010027828A2 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
US20130287688A1 (en) * | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
ES2742379T3 (es) * | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
-
2015
- 2015-10-09 WO PCT/US2015/054960 patent/WO2016057933A1/en active Application Filing
- 2015-10-09 US US15/518,088 patent/US20180265874A1/en not_active Abandoned
- 2015-10-09 CN CN201580055045.1A patent/CN107428825A/zh active Pending
- 2015-10-12 TW TW104133408A patent/TWI669123B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070155685A1 (en) * | 2004-02-27 | 2007-07-05 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
CN102428179A (zh) * | 2009-03-06 | 2012-04-25 | 国立大学法人三重大学 | 用于增强t细胞功能的方法 |
Non-Patent Citations (3)
Title |
---|
JULIE R. BRAHMER 等: "Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 * |
NAPOLEONE FERRARA 等: "DISCOVERY AND DEVELOPMENT OF BEVACIZUMAB,AN ANTI-VEGF ANTIBODY FOR TREATING CANCER", 《NATURE REVIEWS》 * |
姜蕊 等: "人乳头瘤病毒感染与非小细胞肺癌发生的相关性", 《华中科技大学学报(医学版)》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022042537A1 (zh) * | 2020-08-24 | 2022-03-03 | 江苏恒瑞医药股份有限公司 | TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途 |
WO2022174451A1 (zh) * | 2021-02-22 | 2022-08-25 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
Also Published As
Publication number | Publication date |
---|---|
WO2016057933A1 (en) | 2016-04-14 |
TWI669123B (zh) | 2019-08-21 |
TW201625275A (zh) | 2016-07-16 |
US20180265874A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107428825A (zh) | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 | |
Pabla et al. | Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention | |
Pitz et al. | Phase II study of PX-866 in recurrent glioblastoma | |
Chang et al. | Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways | |
Kumar et al. | YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels | |
Bao et al. | Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model | |
CN103399144B (zh) | 用抗体阵列选择乳腺癌治疗药物 | |
Kuang et al. | Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma | |
Thaker et al. | Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors | |
Lin et al. | Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway | |
Kim et al. | Clinical significance of galectin-7 in epithelial ovarian cancer | |
Bergkvist et al. | Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC) | |
Deguchi et al. | PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma | |
JP2020519621A (ja) | 癌を治療するための併用療法 | |
Hanna et al. | A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma | |
Dragovich et al. | Anti-EGFR-targeted therapy for esophageal and gastric cancers: an evolving concept | |
Tang et al. | Upregulation of the δ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo Retraction in/10.3892/ijo. 2023.5504 | |
Fouani et al. | Targeting oncogenic nuclear factor kappa B signaling with redox-active agents for cancer treatment | |
Carlsson et al. | Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors | |
Dai et al. | A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction | |
Lorestani et al. | Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer | |
Zhang et al. | Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma | |
Hinson et al. | Structural alterations in tumor‐draining lymph nodes before papillary thyroid carcinoma metastasis | |
CN102460168B (zh) | 两种抗sparc抗体用于预测对化学疗法的反应的用途 | |
Liang et al. | Low expression of NCOA5 predicts poor prognosis in human cervical cancer and promotes proliferation, migration, and invasion of cervical cancer cell lines by regulating notch3 signaling pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180724 Address after: Xintai City, Taiwan, China Xinjie District Xintai five road 99, 9, 9 Applicant after: Creation of the Limited by Share Ltd Applicant after: Taipei Medical University Address before: No. 17, 3 Park Street, Nangang District, Taipei, Taiwan, China Applicant before: Creation of the Limited by Share Ltd Applicant before: Lin Hongji, Taipei Medical University Applicant before: Lin Hongji |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191011 Address after: Xintai City, Taiwan, China Xinjie District Xintai five road 99, 9, 9 Applicant after: Creation of the Limited by Share Ltd Address before: Xintai City, Taiwan, China Xinjie District Xintai five road 99, 9, 9 Applicant before: Creation of the Limited by Share Ltd Applicant before: Taipei Medical University |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171201 |
|
WD01 | Invention patent application deemed withdrawn after publication |